Introduction
The deregulation of signaling pathways in tumors can lead to enhanced cancer cell growth, proliferation, survival, invasion, and metastasis or reduced apoptosis [1, 2] . Such pathways became the focus of the development of targeted cancer therapies during the last decades [3] [4] [5] . Kinases are of special interest within these systems, either as receptor molecules or downstream regulators of signaling cascades (see Table 1 for an overview of targeted therapies). Examples of receptor kinases to be further discussed in this re-view are the human epidermal growth factor receptors 1 (EGFR) and 2 (HER2). Both kinases are targets for anticancer drugs and can be analyzed for their expression by clinically approved tests, such as immunohistochemistry (IHC) and fluorescence in situ h y b r i d i z a t i o n ( F I S H ) . E G F R o v e r e x p r e s s i o n d u e t o gene amplification is often found in human cancers; in gliomas, this deregulation is often associated with structural rearrangements leading to in-frame deletions in the extracellular domain of the receptor [6] . HER2 overexpression as found in 25 to 30% of human b r e a s t c a n c e r s c a n b e m e d i a t e d e i t h e r b y t r a n s c r i ptional activation or gene amplification [7] [8] [9] [10] . The HER2 status of breast cancer patients does not only have a predictive value, but the receptor itself is also a target for the monoclonal anti-HER2 antibody Trastuzumab [8] . Recent evidence has demonstrated that besides being an important therapeutic target in b reast c ancer , HE R 2 i s a t arget for t he t reat m ent of metastasized gastric cancers [11, 12] , and thus, the anticancer drug Herceptin (Trastuzumab) was app r o v e d f o r t h e t r e a t m e n t o f a d v a n c e d g a s t r i c c a r c inomas. HER2 is currently detected by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), and protocols for the detection of HER2 in gastric cancers by IHC were recently suggested by Rüschoff et al. [13] . H o w e v e r , a l t h o u g h H E R 2 i s well-established as a therapeutic target, recent evidence suggests that down-stream signaling molecules m a y b e b e t t e r p r e d i c t o r s f o r a r e s p o n s e t o a H E R 2 directed therapy than the receptor itself. This follows from the fact that the membrane-bound molecule alone does not necessarily lead to an activation of the signaling cascade. For that reason, identifying the activation status of cancer-related signaling cascades might provide a better insight into the mechanisms underlying the success and failure of targeted therapies, thus providing a useful approach to stratify patients for optimal personalized treatment regimens.
To individualize cancer, biomarker identification has become even more important for the stratification of patients for special treatment regimens. Urokinase-type plasminogen activator (uPA) and its inhibitor plasminogen activator inhibitor-1 (PAI-1) are p r o m i n e n t e x a m p l e s o f s u c h b i o m a r k e r s . B o th are used to provide a more detailed prognosis for nodal-negative breast cancer patients and have reached the highest level of evidence (LOE I) for this purpose [14] . However the level of these two markers can just be determined in fresh-frozen tissue. This is problematic as formalin-fixed, paraffin-embedded (FFPE) tissue is the main source of patient material world wide. Therefore for clinical determination of diagnostic and therapeutic targets new methods are crucially needed to maximize the data that can be gleaned from this kind of tissue. The recently developed method to extract full-length, immunoreactive proteins from FFPE tissues (for review see [15] ) is a major progress for such approaches and provides the means to quantitate clinically relevant proteins like HER2 and analyze cancer-related pathways by reverse phase protein microarray (RPPA) [16] .
Because the field of targeted therapy is growing rapidly, it is important to emphasize the necessity of standardization for pre-analytical as well as analytical settings.
In this review, we shed light on new developments for the detection of therapeutic protein targets and diagnostic biomarkers in clinical tissues and comment on suggestions for the standardization of tissue handling and analysis.
Proteomics of formalin-fixed, paraffin-embedded tissues
Formalin is the standard fixative in clinical tissue collections worldwide and the method of formalin fixation was described in detail in a previous article of the authors [17] . The protein and nucleic acid cross-linking induced by formalin maintains the tissue in an excellent condition for the pathological examination of the morphological characteristics of diseased tissues [18] . W i t h t h e n e w i n t e r e s t i n m acromolecules (DNA, RNA, proteins) as therapeutic targets or biomarkers, scientists began to analyze these entities first in frozen material because FFPE fixation required to preserve the tissue morphology had adverse effects on macromolecules, especially p r o t e i n s . B y a d o p t i o n o f a n t i g e n r e t r i e v a l f i r s t d escribed by Ikeda et al. [19] it was possible to develop an assembly of protocols enabling extraction of proteins from FFPE tissues [18] [19] [20] [21] [22] [23] [24] [25] [26] . An overview of these methods is provided in a recent review by Berg et al., 2010 [15] . Compared to other recent studies [27] [28] [29] [30] , using these protocols non-degraded, full-length, and immunoreactive proteins are obtained and may then be used for protein profiling for enhanced diagnosis. However one should keep in mind that all protocols require high SDS concentrations, temperature and pH, which is problematic for some down-stream applications such as ELISA assays. To assure the integrity of isolated proteins we always do a quantification of the total protein obtained by extraction (Bradford-Assay) and additionally check for correct protein masses by control western blots. Other authors suggest controlling for protein integrity by MS [26, [31] [32] [33] . In the scope of tumor marker research and personalized medicine further aspects of investigation became of major interest: pre-analytical workflow and tissue quality. For molecular diagnostics protein biomarkers need to be precisely measured in high-quality tissue s a m p l e s . I t i s k n o w n t h a t specimens undergo numerous processing steps from the collection of patient samples to the final diagnostic analysis. This aspect of the sample history is very important with regard to the identification of disease-related biomarkers. But so far there were no detailed investigations concerning for example the influence of temperature and time during transportation, fixation method and storage on the molecular integrity of tissue samples. In order of reproducibility of subsequent diagnosis the impact of pre-analytical parameters on biomolecular integrity and expression needs to be analyzed in detail. Furthermore we need guidelines for the standardized collection, handling, stabilization and storage of biosamples and quality assurance indicators for artificial, post collection changes of biological samples. Two large international initiatives are working toward this goal, one funded by the EU (www.spidia.eu) and one by the US (http://biospecimens.cancer.gov). In Table  2 we highlight the most important problems occurring during the pre-analytical phase of sample preparation. These difficulties are also the main focus of the projects mentioned above. The issue of the evaluation of adverse and variable effects of sample preparation i s d i s c u s s e d i n m o r e d e t a i l i n a r e c e n t r e v i e w b y Becker and Taylor [34] .
Reverse Phase Protein Microarrays
Although morphological parameters, namely tumor size, grade and staging, are the most important p a r a m e t e r s f o r d i a g n o s i s , t h e y d o n o t a d d r e s s t h e complexity and heterogeneity of individual tumors at the molecular level [35, 36] [37] . Additionally, several groups demonstrated that there is no constrained correlation between gene transcript levels and protein expression or the functional state of a protein. [38] [39] [40] [41] .
However especially the communication in such a protein network, which is responsible for activation and deactivation of involved proteins, is often altered in cancer and may then lead to aberrant cellular functions that result in proliferation, apoptosis, differentiation, survival, invasion and metastasis. That's why it is of great importance not only to look at the expression of genes or at the activation state of a single protein but to analyze whole protein signaling networks that then can provide fundamental information about the functional state of signaling pathways [42, 43] . One method which meets all demands for such a network monitoring is the reverse phase protein microarray (RPPA). This array format allows the simultaneous analysis of multiple samples for the expression of several proteins under the same experimental conditions even from small numbers of tumor cells or small specimens such as biopsies [44, 45] . Like this changes in protein expression levels or phosphorylation states, before and after treatment, between disease and non-disease states and between responders and non-responders can be monitored [35] . The procedure to generate such an array is simple. After protein extraction from any kind of material (e.g. cells, FFPE tissue or fresh-frozen material), each sample is arrayed in triplicate on nitrocellulose-coated slides u s i n g s e v e r a l d i l u t i o n s t o e n s u r e t h a t e a c h a n alyte/antibody combination can be analyzed in the linear dynamic range. After the spotting each slide may be detected with an antibody against the desired protein (for an overview of the RPPA methodology, see Figure 1 ). However one should keep in mind that for a successful implementation of RPPA highly specific antibodi e s a r e n e e d e d a s o n e c a n ' t d i s t i n g u i s h between different molecular weights (as e.g. in western blot) but only one signal is obtained. Especially for phosphorylated proteins and other posttranslationally modified proteins this seems to be one of the major limiting factors [35, 46] .
Another advantage of the RPPA is the possibility to quantify the total amount of protein in the sample via the application of purified recombinant proteins one the same slide [15, 16] . This method enables to measure protein expression from FFPE tissues more precisely than it is possible by IHC (e.g., for HER2) and implement the analysis of clinical markers, which until now were only measurable from fresh or frozen tissues (e.g. for uPA/PAI-1). This highly quantitative approach is advantageous for patient selection; however, the correlation between protein abundance and histology, as provided by IHC, is lost.
Nevertheless, we successfully established a set of about 50 antibodies for use in RPPA analysis by stringently selecting for specificity and sensitivity by western blot [15, 16] thus providing a starting point f o r t h e a n a l y s i s o f m a j o r c a n c e r -related signaling pathways from FFPE tissues of cancer patients. Based on this expertise we recently developed an algorithm to validate antibodies for their simultaneous application to extract based and classical morphology based methods (Schuster C, Malinowsky K et al., in preparation). With this proposal we plan to combine the advantages of both approaches to get broad insight into all aspects of cancer formation and development.
For the application of RPPA generated data for such a purpose in clinical routine it is necessary to be able to compare the results of arrays generated in different hospitals and experimental settings. This can be achieved by reference samples on each slide, to which the signal may be normalized to. Such a control has to be renewable, reproducible in large-scale, successful over a broad range of end points, stable over a long period of time and as closely related to the test sample as possible [47] . To validate the reproducibility of the method, we performed experiments analyzing the variability between sample preparations, array slides and experimental setups (inter-sample as well as inter-assay comparisons) and found the method to be highly reliable [15] .
I n c o m p a r i s o n t o t h e w i d e l y u s e d E L I S A app r o a c h e s R P P A s a r e m o r e s e n s i t i v e a n d a t w o -site antibody sandwich method is not used, hence there won't be any experimental variability introduced due to labeling yield (or) epitope masking.
Deciphering signaling pathways in clinical tissues for personalized medicine
RPP As c an b e im p lem ent ed in ne ar ly al l a rea s regarding the field of personalized medicine. They are used for the rapid and comprehensive analysis of new drug candidates found by in silico approaches or by binding screens for their biological functions [48] [49] [50] , as well as for biomarker screenings [51] .
Many recent studies have demonstrated that RPPA technology is a very promising tool for signaling pathway profiling of human tissues and cell lines to produce valuable information for the development of new therapeutics or patient selection. Feinberg et al. was the first to utilize a microspot technique to detect antigens in serum [52] . In 2001, another study used RPPAs to show the activation of pro-survival proteins and pathways during prostate cancer progression [45] . In our group, we provided insight into the role of uPA/PAI-1 i n c a n c e r r e l a t e d s i g n a l i n g [16] . Other prominent examples of cancer-specific signaling deregulation namely the activation of the phosphatidylinositol 3-kinase (PI3K) pathway in a significant n u m b e r o f o v a r i a n a n d c o l o n t u m o r s [53, 54] .and, alterations in the mitogen-activated protein kinase (MAPK) pathway or the overexpression of HER2, [8, [53] [54] [55] [56] [57] were summarized in an earlier review by the authors [17] . These examples demonstrate the diverse signaling-based mechanisms underlying cancer progression and indicate that cancer types (e.g., breast c a n c e r ) c a n b e s u b d i v i d e d e . g . , i n t o s m a l l , well-defined subgroups that express a typical protein profile. Some authors go even further, suggesting that the use of a targeted therapy should not be based on the identity of the cancer but rather on the deregulation of a certain pathway [58] . Such an approach would challenge the design of future clinical studies and the approval of new drugs for targeted therapy but could be beneficial for patients by providing highly specific therapies that are only based on the availability of specific targets regardless of the classical characterization of the cancer type. Such a specific treatment could greatly increase the quality of life for patients by minimizing adverse side effects of cancer treatment.
In addition to classical biomarker screenings RPPA is also an adequate tool to compare different t y p e s o f s a m p l e s r e g a r d i n g t h e i r p r o t e i n e xpression profiles. One prominent example is the expression analysis of HER2 from resected tumors versus core needle biopsies. Currently, core biopsies are routinely used for diagnosis of breast cancer and they are often the only sample for providing prognostic and predictive markers before treatment. However, biopsies may not accurately reflect protein expression profiles from the whole tumor. After extraction of full-length proteins from FFPE tissues, Berg et al. used RPPAs to compare HER2, estrogen receptor (ERalpha), and progesterone receptor (PGR) expression levels in a series of 35 FFPE breast cancer surgical specimens and their corresponding core biopsies. We found a high concordance between protein expression in core biopsies and surgical specimens. In this study, the authors could show that HER2, ERalpha, and PGR expression can be assessed reliably on core biopsies of FFPE breast cancer tissues using RRPA. These results might further strengthen the implementation of RPPA technology in routine clinical settings (Berg et al. Protein microarray-based comparison of HER2, estrogen receptor and progesterone receptor status in core biopsies and surgical specimens from FFPE breast cancer tissues. Appl Immunohistochem Mol Morphol., in press 2011).
Our vision: Combined protein and RNA profiling of cancer tissue from the same sample Gene expression profiles (e.g., genes regulating cell cycle, invasion or metastasis) have been proposed as potential biomarkers for the prognosis, prediction of treatment response and the identification of potentially new drugs [59] . In addition to the well-established mRNA profiling, the analysis of small non-coding RNAs called miRNAs has become a focus in biomarker research. In recent years, evidence h a s s u g g e s t e d t h a t w h o l e g r o u p s o r f a m i l i e s o f miRNAs are deregulated in different diseases, especially cancer [60, 61] .
The quantitative analysis of protein expression described in this review may enable the parallel identification of protein and RNA profiles (mRNA and miRNA) using only one FFPE tissue sample. With this method, it is possible to simultaneously determine mutations in critical genes and relate them to expression profiles. Gene mutations frequently lead to a loss of gene function, although the mutated gene is still expressed at the RNA and protein levels. A classical example for such a mutation is the cell adhesion molecule E-cadherin, in which a loss of E-cadherin funct i o n i s f o u n d i n m a n y d i f f u s e -type gastric cancers, although the protein is expressed at high levels in these tumors [62] . Another useful application of the combined DNA and protein analysis is the utilization of EGFR as a therapeutic target; although EGFR expression is detectable on a protein level, many patients with colorectal cancers do not respond to Cetuximab therapy [63] [64] [65] . The downstream target of E G F R i s m u t a t e d i n m a n y o f t h e n o n -responders, therefore blocking the EGFR does not inhibit proliferative signaling. Therefore, the parallel assessment of the level of EGFR protein and the mutational status o f t h e E G F R g e n e i s o n e i m p o r t a n t p r e r e q u i s i t e f o r successful Cetuximab treatment [63] [64] [65] . The remaining EGFR-positive patients express the wild-type form of the protein and provide a good example for the need of additional biomarkers for the prediction of therapeutic response. Many of these patients do not respond to Cetuximab therapy, probably due to further alterations in pathways downstream of EGFR. In recent years, several additional candidate biomarkers of EGFR resistance were suggested. Molecular aberrations occur in BRAF, PIK3CA and PTEN, which are known downst r e a m e f f e c t o r s o f E G F R [66] [67] [68] [69] . Som a t i c m u t a t i o n s i n t h e s e E G F R e f f e c t o r s c o r r e l a t e w i t h t h e r e d u c e d e f f i c a c y o f C e t u x i m a b i n p a t i e n t s with metastatic colorectal cancers [70, 71] . An activating mutation of BRAF, which lies downstream of the EGFR signaling cascade, was found in a proportion of patients with wild-type EGFR that do not respond to Cetuximab treatment [66] . For that reason, BRAF mutational analysis is currently recommended by the National Comprehensive Cancer Network (NCCN) clinical guidelines for patients with "wild type" metastatic or recurrent colorectal cancers that are receiving Cetuximab [72] .
Recently, we succeeded in the parallel extraction of proteins and RNA, including miRNA, f r o m t h e same FFPE tissue sample (Malinowsky et al.; unpublished data) , demonstrating the proof of principle of our vision. While FFPE samples are a large challenge of the clinical application of the combined analysis of protein and RNA, new formalin-free fixatives, e.g. PAXgene tissue fixation and stabilization reagents [73] , HOPE [74] [75] [76] , RCL2 [77] [78] [79] , Finefix [80] , metacarn [81] or Umfix [82] show great potential to serve as novel multimodal fixatives for modern pathology, enabling extensive protein biomarker studies on clinical tissue samples. Regardless of the nature of the fixative, our approach allows the integration of analysis at all three levels of gene expression (DNA, RNA and protein), providing insight into the whole spectrum of potential biomarkers ( Figure  2 ). 
Conclusions
In the scope of new targeted cancer therapy approaches new technologies which meet the issues of fast and precise target detection and quantification are desperately needed. RPPA is a very promising tool in this regard. It has already been implemented in seve r a l b i o m a r k e r s t u d i e s a n d b e c o m e s e v e n m o r e p owerful when combined with the huge sample reserv o i r p r o v i d e d b y F F P E t i s s u e s . I t i s c l e a r n o w t h a t proteins can be extracted from FFPE tissues and reliably analyzed. We believe that applying these new techniques -probably in conjunction with novel tissue fixatives -w i l l g r e a t l y f a c i l i t a t e t h e s e a r c h f o r n e w biomarkers and therapeutic targets in the near future. More importantly, the great translational potential of the new approaches are apparent as the methodologies discussed can easily combine classic histopa-thology and modern multiplex protein profiling. However, in depth evaluation of antibodies and the use and design of proper controls for tissue quality are essential.
